Key facts

Active Substance
Dapirolizumab pegol
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0439/2020
PIP number
EMEA-002702-PIP01-19
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Treatment of Systemic Lupus Erythematosus (SLE)
Route(s) of administration
Intravenous use
Contact for public enquiries

UCB Biopharma SRL

Tel.  +44 1753777100
E-mail: UCBCares.UK@ucb.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page